Target Validation Information
Target ID T86885
Target Name Beta-2-glycoprotein 1
Target Type
Action against Disease Model LJP-1082 LJP-1082 was conjugated to a defined, non-immunogenic organic platform to generate a tetravalent presentation of LJP-1082 for use as a toleragen. Tetravalent LJP-1082 induced a dose-dependent reduction in antibody levels in mice previously immunized and boosted with LJP-1082 coupled to the carrier keyhole limpet hemocyanin. These experiments support the technical feasibilityof a tolerance-based approach for reducing anti-beta2-GPI antibodies in vivo. [553284] Drug Info
The Effect of Target Knockout, Knockdown or Genetic Variations The antiphospholipid syndrome is characterized by the presence in ser uM of autoantibodies against beta2GPI. Although the role of beta2GPI in the pathogenesis of antiphospholipid antibody syndrome (APS) is well recognized, its exact physiological functions still remain undisclosed. Several interactions of beta2GPI with components of the coagulation cascade have been proposed, resulting in both procoagulant and anticoagulant effects. Additionally, beta2GPI has been implicated in the mechanism of recurrent fetal loss entailed in APS. Recently, using a homologous recombination approach, reproduction of mice homozygous for deletion of the beta2GPI gene has been feasible. beta2GPI knockout mice offer a valuable tool for revealing the physiological role of the protein. These mice show decreased in vitro ability for thrombin generation. Furthermore, although mice lacking beta2GPI are fertile, the success of early pregnancy is moderately compromised and functional beta2GPI is believed necessary for optimal implantation and placental morphogenesis. [553284]
Ref 553284A chemically defined, toleragen-based approach for targeting anti-beta2-glycoprotein I antibodies. Lupus. 1998;7 Suppl 2:S166-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.